无创通气中主流与旁流呼气末二氧化碳监测的准确性评估:一项随机交叉试验(MASCAT-NIV试验)
本研究为混合ICU内随机、开放标签交叉试验,纳入拔管后计划行无创通气且呼气末与动脉血二氧化碳分压差≤5 mmHg的患者60例,比较面罩内杯主流式(新方法)与旁流式(原方法)二氧化碳监测。新方法r=0.92(P<0.001),平均偏差2.70 mmHg(95%CI 2.15-3.26),95%一致性界限-1.61至7.02 mmHg;原方法r=0.79(P<0.001),平均偏差6.22 mmHg(95%CI 5.22-7.23),95%一致性界限-1.54至13.99 mmHg。作者认为新方法在无创通气期间可采集与插管时同样充分的呼气样本,连续呼气末二氧化碳联合外周血氧饱和度监测有望用于拔管后高危患者呼吸衰竭的早期识别。
要点
- 拔管后无创通气患者中,面罩内杯主流式呼气末二氧化碳与动脉血二氧化碳相关性r=0.92(P<0.001),优于旁流式r=0.79(P<0.001)。
- 新方法平均偏差2.70 mmHg(95%CI 2.15-3.26),95%一致性界限-1.61至7.02 mmHg,与自主呼吸试验时结果相似(平均偏差2.51,95%CI 2.00-3.02,95%一致性界限-1.45至6.47 mmHg)。
- 原方法平均偏差6.22 mmHg(95%CI 5.22-7.23),95%一致性界限-1.54至13.99 mmHg,偏差大于新方法。
- 作者认为无创通气期间新方法可采集与插管时同样充分的呼气样本。
- 作者认为连续呼气末二氧化碳联合外周血氧饱和度监测有望用于拔管后高危患者呼吸衰竭的早期识别。
适用人群与场景
- 混合ICU中拔管后计划行无创通气、且呼气末二氧化碳与动脉血二氧化碳分压差≤5 mmHg的患者。
诊断标准与关键阈值
- 纳入条件:拔管后计划行无创通气,且呼气末二氧化碳与动脉血二氧化碳分压差≤5 mmHg。
研究设计与关键结果
- 研究类型:随机、开放标签交叉试验,在混合ICU进行;2020年4月至2021年10月纳入60例患者。
- 干预与对照:面罩内杯主流式二氧化碳监测(新方法)对比旁流式二氧化碳监测(原方法),均在无创通气期间进行。
- 相关性:新方法r=0.92(P<0.001);原方法r=0.79(P<0.001)。
- 一致性:新方法平均偏差2.70 mmHg(95%CI 2.15-3.26),95%一致性界限-1.61至7.02 mmHg;自主呼吸试验时平均偏差2.51 mmHg(95%CI 2.00-3.02),95%一致性界限-1.45至6.47 mmHg;原方法平均偏差6.22 mmHg(95%CI 5.22-7.23),95%一致性界限-1.54至13.99 mmHg。
- 作者结论:新方法在预测动脉血二氧化碳方面优于原方法;无创通气期间新方法可采集与插管时同样充分的呼气样本;连续呼气末二氧化碳联合外周血氧饱和度监测有望用于拔管后高危患者呼吸衰竭的早期识别。
- 试验注册:UMIN-CTR UMIN000039459,注册日期2020年2月11日。
证据类型、等级与局限
- 证据类型:随机、开放标签交叉试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为无创通气期间面罩内杯主流式呼气末二氧化碳监测在预测动脉血二氧化碳方面优于旁流式。
- 作者认为连续呼气末二氧化碳测量联合外周血氧饱和度监测有望用于拔管后高危患者呼吸衰竭的早期识别。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The end-tidal partial pressure of carbon dioxide (PETCO2) can be used to estimate the arterial partial pressure of carbon dioxide (PaCO2) in patients who undergo mechanical ventilation via endotracheal intubation. However, no reliable method for measuring PETCO2 during noninvasive ventilation (NIV) has been established. The purpose of this study was to evaluate the correlation and agreement between PaCO2 and PETCO2 measured by these two methods and to compare them in patients who underwent NIV after extubation.
METHODS: This study was a randomized, open-label, crossover trial in a mixed intensive care unit. We included patients who were planned for NIV after extubation and for whom the difference between PETCO2 and PaCO2 was ≤ 5 mmHg. We compared mainstream capnography using an inner cup via face mask (the novel method) with sidestream capnography (the previous method) during NIV. The relationships between PaCO2 and PETCO2 were evaluated by computing the Pearson correlation coefficient, and the agreement between PaCO2 and PETCO2 was estimated using the Bland-Altman method.
RESULTS: From April 2020 to October 2021, 60 patients were included to the study. PaCO2 and PETCO2 were well correlated in both methods (the novel methods: r = 0.92, P < 0.001; the previous method: r = 0.79, P < 0.001). Mean bias between PaCO2 and PETCO2 measured using the novel method was 2.70 (95% confidence interval [CI], 2.15-3.26) mmHg with 95% limits of agreement (LoA) ranging from - 1.61 to 7.02 mmHg, similar to the result of measurement during SBT (mean bias, 2.51; 95% CI, 2.00-3.02; 95% LoA, - 1.45 to 6.47 mmHg). In contrast, measurement using the previous method demonstrated a larger difference (mean bias, 6.22; 95% CI, 5.22-7.23; 95% LoA, - 1.54 to 13.99 mmHg).
CONCLUSION: The current study demonstrated that the novel PETCO2 measurement was superior to the previous method for PaCO2 prediction. During NIV, the novel method may collect as sufficient exhalation sample as during intubation. Continuous PETCO2 measurement combined with peripheral oxygen saturation monitoring is expected to be useful for early recognition of respiratory failure among high-risk patients after extubation. Trial registration UMIN-CTR UMIN000039459. Registered February 11, 2020.
参考来源
- Sakuraya M, Douno E, Iwata W, et al. Accuracy evaluation of mainstream and sidestream end-tidal carbon dioxide monitoring during noninvasive ventilation: a randomized crossover trial (MASCAT-NIV trial). J Intensive Care. 2022. PMID: 35303968. doi:10.1186/s40560-022-00603-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。